Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
about
Cellular interplay between neurons and glia: toward a comprehensive mechanism for excitotoxic neuronal loss in neurodegenerationTargeting amyloid-beta in glaucoma treatment.Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice.Assessment of neuroprotection in the retina with DARC.Current concepts in the pathophysiology of glaucomaPathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis(propyl)-cognitin.In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death.Hydrogen Sulfide Epigenetically Attenuates Homocysteine-Induced Mitochondrial Toxicity Mediated Through NMDA Receptor in Mouse Brain Endothelial (bEnd3) Cells.Down-regulation of the RNA editing enzyme ADAR2 contributes to RGC death in a mouse model of glaucoma.Characterization of the early CNS stress biomarkers and profiles associated with neuropsychiatric diseases.Ageing and neuronal vulnerability.Neuroprotection of rat retinal ganglion cells mediated through alpha7 nicotinic acetylcholine receptors.Anti-dementia drugs and hippocampal-dependent memory in rodents.Presynaptic NMDA receptor mechanisms for enhancing spontaneous neurotransmitter release.Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic propertiesTherapeutic perspectives for the treatment of Huntington's disease: treating the whole bodyMemantine: efficacy and safety in mild-to-severe Alzheimer's disease.Emerging Synaptic Molecules as Candidates in the Etiology of Neurological Disorders.New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases.THE ROLE OF INTRACELLULAR SODIUM (Na) IN THE REGULATION OF CALCIUM (Ca)-MEDIATED SIGNALING AND TOXICITY.Imaging apoptosis in the eye.Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.Nanotechnology based theranostic approaches in Alzheimer's disease management: Current status and future perspective.GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects.Post-acute delivery of memantine promotes post-ischemic neurological recovery, peri-infarct tissue remodeling, and contralesional brain plasticity.Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.Ketamine and chronic pain--going the distance.NMDA Receptors as Potential Therapeutic Targets in Diabetic Nephropathy: Increased Renal NMDA Receptor Subunit Expression in Akita Mice and Reduced Nephropathy Following Sustained Treatment With Memantine or MK-801.Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo.Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation.Extrasynaptic NMDA receptor-induced tau overexpression mediates neuronal death through suppressing survival signaling ERK phosphorylation.The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma.Ethanolic extract of Streblus asper leaves protects against glutamate-induced toxicity in HT22 hippocampal neuronal cells and extends lifespan of Caenorhabditis elegans.Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report.Altered Synaptic and Extrasynaptic NMDA Receptor Properties in Substantia Nigra Dopaminergic Neurons From Mice Lacking the GluN2D Subunit
P2860
Q24654460-3317171E-C86E-4BCE-B236-DF76562DB16CQ24681763-D3081B45-B629-495F-B332-5D361234B282Q33263907-D6BDA69C-76D2-444C-A8D5-20A4534CE6C6Q33377667-156B1425-F7EB-4B94-9536-A0399311BC5AQ33477806-A8E1A398-B864-4518-A55C-54ABD2E1311AQ33924304-13E9399F-6D09-4B6A-BFAD-393374293E22Q34662307-3A926819-BE2F-40D4-B57E-83AC2EEE0FD3Q35009206-80AAC80F-C8D9-4912-B3A0-08D9961EBB84Q35114509-D523A54D-2052-4BB5-86AF-0A1540736CB4Q36186439-C139EDB0-E066-479D-9BB9-FAD6C861FC45Q36428039-9081C528-225B-48B6-ACAF-3B85FA029C82Q36721586-C1FCD13E-4E30-4138-AA0E-FC9FD14EE19AQ36925129-A3F328A7-E263-4869-8B90-929607408604Q36944228-FF4C8DD8-37E7-4F71-A56C-7F6021791B53Q36967194-764D65F5-874E-4BAD-8060-D683F4894BC6Q36999830-85D18AC8-0EBC-452B-8B1B-096BFFE1E491Q37125743-C12D43F5-682F-482C-8ACA-4A9EED999CDAQ37694175-9469FAC4-27D4-404F-98D4-EBC2DB484892Q37703489-1E9152E7-EAFB-497D-85F4-777784727BF9Q37829641-8B862D53-E805-4988-9D9D-2CA4DFEA1695Q38375518-6EABAE37-9C09-4019-8BEB-E6A336E067BCQ38632327-8291A4D1-D680-44EB-82FB-2568B69FD602Q38686370-12ADB07D-93BF-40E4-B4B4-541A4D3EDAC5Q38854549-07F2EE3C-4A58-417D-ACE0-D65E2CB3A8C1Q39773096-2D9ADB45-A0FF-435A-84FF-1F0FEC04AE28Q39818021-4F5E4B09-4373-40F4-B1B5-7F2703C18F01Q40723289-706A7C25-A896-4707-896C-DE41E732B016Q41640119-6ACAA38D-8AE9-4234-A828-78480FE69007Q42096215-F84D5C60-2ED7-48DC-9B08-D72312CE2F67Q42113213-C39E34F5-F5FC-463F-91DA-E90CD2E6BC87Q42328278-10F9DF24-A059-4F0F-852C-74428F037849Q42748164-F1EF7DC2-4E7A-43C0-92CE-72CEC46BAB3AQ47141490-25CEEC86-2C39-44BA-906A-C95EA9C6A384Q55230164-3FF0154A-E085-4926-88EB-75B06AC8C8C9Q58572690-D9D43C84-B380-46E4-815D-02E3446B4FF4
P2860
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Paradigm shift in NMDA recepto ...... nd other neurologic disorders.
@ast
Paradigm shift in NMDA recepto ...... nd other neurologic disorders.
@en
type
label
Paradigm shift in NMDA recepto ...... nd other neurologic disorders.
@ast
Paradigm shift in NMDA recepto ...... nd other neurologic disorders.
@en
prefLabel
Paradigm shift in NMDA recepto ...... nd other neurologic disorders.
@ast
Paradigm shift in NMDA recepto ...... nd other neurologic disorders.
@en
P356
P1476
Paradigm shift in NMDA recepto ...... and other neurologic disorders
@en
P2093
Stuart A Lipton
P304
P356
10.3233/JAD-2004-6S610
P433
P577
2004-12-01T00:00:00Z